[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,200
Citations 0
Viewpoint
August 2015

The Future of Research in Multiple Sclerosis

Author Affiliations
  • 1Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
  • 2Biogen, Boston, Massachusetts
JAMA Neurol. 2015;72(8):853-854. doi:10.1001/jamaneurol.2015.0270

Over the past 2 decades, advances in immunology, imaging, and experimental therapeutics have led to dramatic progress in understanding and treating multiple sclerosis (MS). Currently, there are more than 12 US Food and Drug Administration–approved therapies for MS, with more in development. Magnetic resonance imaging has been shown to be useful both in screening novel anti-inflammatory therapies in phase 2 trials and in identifying patients with suboptimal treatment response in clinical practice. Pharmacologic and other treatment approaches have demonstrated effectiveness in alleviating symptoms and compensating for disability. Despite these advances, there remain many critical needs in understanding and treating MS.

First Page Preview View Large
First page PDF preview
First page PDF preview
×